D.E. Shaw & Co
TXG icon

D.E. Shaw & Co’s 10x Genomics TXG Stock Holding History

D.E. Shaw & Co’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.94M Buy
233,069
+164,512
+240% +$4.31M ﹤0.01% 1916
2026
Q1 		$1.46M Sell
68,557
-105,911
-61% -$2.12M ﹤0.01% 3158
2025
Q4 		$2.85M Buy
174,468
+11,560
+7% +$175K ﹤0.01% 2763
2025
Q3 		$1.9M Sell
162,908
-583,358
-78% -$7.61M ﹤0.01% 3015
2025
Q2 		$8.64M Sell
746,266
-1,235,997
-62% -$11.3M 0.01% 1604
2025
Q1 		$17.3M Buy
1,982,263
+763,665
+63% +$9.63M 0.02% 1036
2024
Q4 		$17.5M Buy
+1,218,598
New +$19.2M 0.01% 1111
2024
Q2 		– Sell
-64,799
Closed -$2.43M – 4858
2024
Q1 		$2.43M Buy
64,799
+59,855
+1,211% +$2.63M ﹤0.01% 2478
2023
Q4 		$277K Sell
4,944
-55,361
-92% -$2.41M ﹤0.01% 3770
2023
Q3 		$2.49M Sell
60,305
-47,225
-44% -$2.46M ﹤0.01% 2399
2023
Q2 		$6M Buy
107,530
+97,299
+951% +$5.27M 0.01% 1725
2023
Q1 		$571K Sell
10,231
-184,026
-95% -$8.59M ﹤0.01% 3494
2022
Q4 		$7.08M Buy
+194,257
New +$6.35M 0.01% 1767
2021
Q4 		– Sell
-3,402
Closed -$495K – 5726
2021
Q3 		$495K Sell
3,402
-32,334
-90% -$5.55M ﹤0.01% 4088
2021
Q2 		$7M Sell
35,736
-55,177
-61% -$9.99M 0.01% 1774
2021
Q1 		$16.5M Sell
90,913
-115,104
-56% -$19.9M 0.02% 1041
2020
Q4 		$29.2M Buy
206,017
+63,898
+45% +$9.27M 0.03% 760
2020
Q3 		$17.7M Buy
+142,119
New +$14.9M 0.02% 899
2020
Q2 		– Sell
-10,973
Closed -$684K – 4264
2020
Q1 		$684K Buy
10,973
+6,970
+174% +$544K ﹤0.01% 3020
2019
Q4 		$305K Buy
+4,003
New +$241K ﹤0.01% 3620

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

D.E. Shaw & Co's TXG Position: Q2 2026 in Review

D.E. Shaw & Co increased its 10x Genomics (TXG) stake by 240% in Q2 2026, buying an estimated $4.31M and bringing the position to 233,069 shares worth $8.94M. The position accounts for ﹤0.01% of the portfolio, ranked #1916.

D.E. Shaw & Co first reported a position in TXG in Q4 2019 and has held it in 20 quarters since. The position peaked at $29.2M in Q4 2020. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • D.E. Shaw & Co held 233,069 shares of 10x Genomics worth $8.94M as of Q2 2026.
  • D.E. Shaw & Co bought 164,512 10x Genomics shares in Q2 2026, an estimated $4.31M.
  • 10x Genomics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #1916 holding.
  • D.E. Shaw & Co first reported a position in 10x Genomics in Q4 2019 and has held it in 20 quarters since.
  • D.E. Shaw & Co's 10x Genomics position peaked at $29.2M in Q4 2020.
  • 392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.